As experts on US market access, CELforPharma faculty members Nick Proctor and Louisa Oliver Byrne, expert-trainers of the Understanding Pharma Market Access in the US course, have been closely monitoring the evolution of drug pricing reforms, with particular attention to the Most Favored Nation (MFN) proposals. These proposals aim to tie the prices of certain medicines in the US to the lowest list prices available across a set of OECD countries, and they have the potential to reshape both the American and global pharmaceutical markets.
The future of MFN remains uncertain. Proposals have faced political, legal, and operational hurdles, and their implementation could vary greatly depending on administration priorities. The debate nevertheless highlights persistent political and public pressure for drug pricing reform in the US.
This insight is based on the whitepaper “Market Access in the IRP Era: Scenarios to Plan for an Uncertain Future (2025)”, authored by Nick Proctor and Louisa Oliver Byrne. The full paper is available for download here.